1224945-44-1

Basic information

• Product Name: tert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate
• Synonyms: tert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate
• CAS NO: 1224945-44-1
• Molecular Weight: 326.233
• Mol File: 1224945-44-1.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate(1224945-44-1)
• EPA Substance Registry System: tert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate(1224945-44-1)

Safety Data

• Hazardous Substances Data: 1224945-44-1(Hazardous Substances Data)

Upstream product

• 1311994-51-0 N-Boc-(2-bromobenzyl)-(3-chloropropyl)amine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 116861-31-5 tert-butyl N-(3-chloropropyl)carbamate 
• 129540-24-5 2-(2-bromophenyl)pyrrolidine 

Downstream Products

• 1311994-64-5 C₂₇H₂₆N₂O₄S 
• 1311994-59-8 ethyl 1-(benzenesulfonyl)-3-{2-[1-(tert-butylcarbonyl)pyrrolidin]phenyl}-1H-indole-2-carboxylate 
• 1311994-55-4 C₂₁H₃₂BNO₄ 

Relevant articles and documents

1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES

The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

BCL-2 INHIBITORS

The disclosure includes compounds of Formula (I), (I) wherein Z, Q1, Q3, Q4, Q5, Q6, Q7, R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, g, k, m, n, s, v, j, L, Z1, and, W are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Rigid analogues of antimitotic indolobenzazepinones: New insights into tubulin binding via molecular modeling

Two rigid analogues of 5-ethylindolobenzazepinone 4, a potent cytotoxic agent and inhibitor of tubulin polymerization, were prepared. The first was the indane derivative 5, in which the ethyl group is attached to the benzo moiety. The second was the pyrro

(PYRROLIDIN-2-YL)PHENYL DERIVATIVES

The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula I wherein R1 is (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, or halo(C1-4)alkyloxy; R2 is H, (C

( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN

The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula (I), wherein R1 is (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, or halo(C1-4)alkyloxy; R2 is H, (Cs